-

Shape Memory Medical Names Mary Dennehy as Vice President of Marketing

SANTA CLARA, Calif.--(BUSINESS WIRE)--Shape Memory Medical Inc., developer of innovative therapies for cardiovascular and neurovascular markets, is pleased to announce and welcome Mary Dennehy as Vice President of Marketing. Mary will be responsible for driving the development and implementation of global marketing strategies and initiatives that support commercialization of its Shape Memory Polymer embolization products and therapies.

Mary brings over 20 years of medical device experience with organizations ranging from early stage start-ups to established global market leaders in the cardiovascular and orthopedic spine industries. Mary recently spent seven years at Endologix as Director of Global Marketing and later as Senior Director of Clinical Marketing and Health Economics with a focus on market development for the company’s aortic endovascular therapies. Prior to these roles, Mary held senior-level product and corporate marketing positions in the U.S. and abroad at Kyphon (acquired by Medtronic) and Guidant Vascular Intervention (acquired by Abbott Vascular). Mary’s marketing career also includes Syntactx, a premier global clinical research organization, and the world-renowned Arizona Heart Institute.

"As we continue to grow as an emerging global leader in therapies for peripheral embolization, hemorrhagic aneurysms and endovascular aortic aneurysms, Mary’s broad leadership and experience will help make that vision a reality,” said Ted Ruppel, President and Chief Executive Officer of Shape Memory Medical Inc. “Mary’s proven background in market development, product launch, and communications will be crucial to our successful market growth. She also comes to us with a long history of collaborative relationships within the vascular community that will enable us to further advance our product development and clinical research initiatives.”

“I am very excited to join the Shape Memory Medical team and to be a part of an organization with such an innovative and unique portfolio,” said Mary of her new position. “I truly believe that our technology has great potential to address several unmet clinical needs, and I am particularly excited about our clinical work in the aortic aneurysm space. We announced last week the initiation of the prospective AAA-SHAPE study looking at the use of the IMPEDE-FX Embolization Plug to treat the abdominal aortic aneurysm sac during traditional EVAR procedures, and I look forward to working together with the physician community along this journey.”

Mary earned a Bachelor of Science degree from Penn State University, a Master of Business Administration from the Franciscan University of Steubenville, and a Master of Health Administration from the University of Phoenix.

About Shape Memory Medical

Shape Memory Medical Inc., based in Santa Clara, California, is dedicated to developing innovative therapeutic solutions with its proprietary Shape Memory Polymers. Neurovascular embolization products include the TrelliX® Embolic Coil; CE marked for use in the EU. Peripheral embolization products include the IMPEDE® and IMPEDE-FX Embolization Plugs; both CE marked for use in the EU and cleared for use in the United States (US). In the United States, the IMPEDE-FX Embolization Plug is currently indicated for use with the IMPEDE Embolization Plug to obstruct or reduce the rate of blood flow in the peripheral vasculature. In countries recognizing CE marking, the IMPEDE-FX Embolization Plug is indicated for use to obstruct or reduce the rate of blood flow in the peripheral vasculature. For more information, visit www.shapemem.com.

Contacts

Mary Dennehy
m.dennehy@shapemem.com
602-908-9812

Shape Memory Medical Inc.

Details
Headquarters: San Jose, CA
CEO: Edward Ruppel
Employees: 25-50
Organization: PRI

Release Versions

Contacts

Mary Dennehy
m.dennehy@shapemem.com
602-908-9812

More News From Shape Memory Medical Inc.

Shape Memory Medical Announces Midway Milestone in the AAA-SHAPE Randomized Controlled Pivotal Trial

SAN JOSE, Calif.--(BUSINESS WIRE)--Shape Memory Medical Inc., developer of the only commercially available volume-expanding shape memory polymer for endovascular embolization applications, announced it has reached 50 percent enrollment in its ongoing AAA-SHAPE Pivotal Trial, the Company’s prospective, multicenter, randomized, open-label trial to determine safety and effectiveness of the IMPEDE-FX RapidFill® Device to improve abdominal aortic aneurysm (AAA) sac behavior when used in conjunction...

Shape Memory Medical Announces Approvals for the IMPEDE Embolization Plug Product Family in Singapore and Malaysia

SAN JOSE, Calif.--(BUSINESS WIRE)--Shape Memory Medical Inc., the innovator of the only commercially available volume-expanding shape memory polymer for endovascular embolization applications, announced today that it has received approvals from both Singapore’s Health Science Authority (HSA) and Malaysia’s Medical Device Authority (MDA) to market the IMPEDE Embolization Plug, the IMPEDE-FX Embolization Plug, and the IMPEDE-FX RapidFill System. Getz Healthcare Pty Ltd, which is a member of the p...

Shape Memory Medical Completes Enrollment in the EMBO-Post Market Surveillance Registry

SAN JOSE, Calif.--(BUSINESS WIRE)--Shape Memory Medical Inc., the innovator of shape memory polymer for endovascular applications, announced the completion of patient enrollment in the EMBO Post Market Surveillance (EMBO-PMS) Registry, the Company’s prospective, multicenter registry of the IMPEDE and IMPEDE-FX Embolization Plugs, and IMPEDE-FX RapidFill Device when used for peripheral vascular embolization. “Reaching this milestone in our clinical program marks a significant step forward,” said...
Back to Newsroom